Stock ABBV ABBVIE INC.
Add to a list
To use this feature you must be a member
Log inSign up

News AbbVie Inc. NEO Exchange

Equities

ABBV

CA00288K1084

End-of-day quote NEO Exchange
Other stock markets
 23:00:00 27/06/2024 BST 		5-day change 1st Jan Change
25 CAD +1.46% Intraday chart for AbbVie Inc. +0.36% +10.28%
06-28 Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU MT
06-28 AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
AbbVie - Introducing Alle Payment Plans, Powered by Cherry
AQ
Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU
MT
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment
MT
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
PR
AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
CI
Health Care Stocks Fall With Broad Market -- Health Care Roundup
DJ
Sector Update: Health Care Stocks Slipping Late Afternoon
MT
Sector Update: Health Care Stocks Decline in Afternoon Trading
MT
AbbVie: acquisition of Celsius for $250 million
CF
AbbVie Buys Celsius Therapeutics for $250 Million
DJ
AbbVie Buys Celsius Therapeutics for $250 million
MT
AbbVie Buys Celsius Therapeutics for $250 million
MT
AbbVie Acquires Celsius Therapeutics in $250 Million Cash Deal
MT
AbbVie Acquires Celsius Therapeutics
PR
AbbVie - U.S. Food and Drug Administration Grants Second Approval for EPKINLY to Treat Patients with Relapsed or Refractory Follicular Lymphoma
AQ
Introducing Allē Payment Plans, Powered by Cherry
PR
Nxera Pharma Co Achieves Key R&D Milestone in Collaboration with AbbVie; Secures $10 Million Payment
MT
Nxera Pharma Co., Ltd. Receives USD 10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone
CI
U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma
PR
U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ABBV Stock
  4. ABBV Stock
  5. News AbbVie Inc.